CNR1 and Hepatic fibrosis: Analysis of the signaling properties of the heteromer has shown that AT1 receptor agonists induce a rapid, dose-dependent increase in ERK1/2 phosphorylation, which is potentiated by CB1 receptor agonists and blocked by CB1 antagonists, suggesting that the CB1-AT1 heteromer may be a possible novel therapeutic target in the treatment of liver fibrosis.